Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | TOP1 | P11387 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14555509 | 0.96 | PTGS2 (0.45) | PTGS1PTGS2PDK2ALDH1A1HSD17B10 | |
| SCHEMBL15723954 | 0.92 | PTGS2 (0.41) | PTGS1PTGS2PDK2ALDH1A1HSD17B10 | |
| SCHEMBL7559743 | 0.86 | PDK2 (0.42) | PTGS1PTGS2PDK2ALDH1A1HSD17B10 | |
| SCHEMBL22601441 | 0.86 | MAPT (0.39) | PDK2ALDH1A1HSD17B10HTTKCNA5 | |
| SCHEMBL15723877 | 0.84 | COMT (0.46) | PDK2ALDH1A1GCGRHPGDPOLB | |
| SCHEMBL20466883 | 0.83 | PTGS1 (0.39) | PTGS1PTGS2PDK2ALDH1A1HSD17B10 | |
| SCHEMBL7556356 | 0.83 | ALDH1A1 (0.41) | PTGS1PTGS2PDK2ALDH1A1HSD17B10 | |
| SCHEMBL9963326 | 0.82 | GCGR (0.42) | PTGS2TOP1GCGR | |
| SCHEMBL15723977 | 0.82 | CYP2A6 (0.52) | PTGS2ALDH1A1HSD17B10HTTKCNA5 | |
| SCHEMBL18853955 | 0.82 | TDP1 (0.41) | PTGS1PTGS2ALDH1A1HSD17B10GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210217973-A1 | Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues | UNIV ARIZONA STATE (US) | 2021-07-15 | — | — | US | disclosed |
| US-11011712-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20210009557-A1 | ACYCLIC CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180223045-A1 | POLYIMIDE PRECURSOR COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2018-08-09 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9941479-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| EP-3185332-A1 | ORGANIC LIGHT-EMITTING DEVICE | Samsung Display Co., Ltd. (KR) | 2017-06-28 | — | — | EP | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | PTGS1 1484/4885PTGS2 2700/4885PDK2 3460/4885 |
| US-11011712-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | DPYD, DCTD, TYMP | PTGS1 2771/4885PTGS2 3525/4885PDK2 1289/4885 |
| US-20210217973-A1 | Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues | DPYD, DCTD, TYMP | PTGS1 2771/4885PTGS2 3525/4885PDK2 1289/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | PTGS1 1484/4885PTGS2 2700/4885PDK2 3460/4885 |
| US-20210009557-A1 | ACYCLIC CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCR3, CXCR1 | PTGS1 778/4885PTGS2 1348/4885PDK2 860/4885 |
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | PTGS1 816/4885PTGS2 2558/4885PDK2 1241/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | PTGS1 1484/4885PTGS2 2700/4885PDK2 3460/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | PTGS1 1484/4885PTGS2 2700/4885PDK2 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.